Humana (NYSE:HUM - Get Free Report) had its price objective hoisted by equities researchers at TD Cowen from $370.00 to $430.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a "hold" rating on the insurance provider's stock. TD Cowen's price objective would indicate a potential downside of 3.11% from the company's current price.
Several other analysts also recently weighed in on the stock. Leerink Partners raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $513.00 target price on the stock in a research report on Thursday, July 30th. Cantor Fitzgerald raised their price target on shares of Humana from $460.00 to $495.00 and gave the stock an "overweight" rating in a report on Monday. Robert W. Baird raised shares of Humana from a "neutral" rating to an "outperform" rating and raised their price target for the stock from $390.00 to $596.00 in a report on Friday, October 9th. HSBC downgraded shares of Humana to a "hold" rating in a research note on Thursday, July 30th. Finally, Mizuho boosted their price objective on shares of Humana from $468.00 to $495.00 and gave the company an "outperform" rating in a report on Tuesday, October 13th. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $472.17.
View Our Latest Analysis on Humana
Humana Stock Up 1.3%
Humana stock traded up $5.76 during midday trading on Wednesday, reaching $443.82. The company's stock had a trading volume of 655,404 shares, compared to its average volume of 1,643,430. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.74. The stock has a market capitalization of $53.29 billion, a P/E ratio of 43.21, a PEG ratio of 2.46 and a beta of 0.65. The stock's 50-day simple moving average is $405.76 and its 200-day simple moving average is $313.90. Humana has a 52-week low of $163.11 and a 52-week high of $456.50.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The business had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. During the same quarter in the previous year, the firm earned $3.24 earnings per share. The company's revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. On average, sell-side analysts expect that Humana will post 9.57 EPS for the current year.
Institutional Trading of Humana
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC grew its position in Humana by 60.8% during the 3rd quarter. Private Advisor Group LLC now owns 2,760 shares of the insurance provider's stock worth $1,053,000 after purchasing an additional 1,044 shares during the period. Focus Advisor Solutions LLC raised its stake in shares of Humana by 178.3% during the 3rd quarter. Focus Advisor Solutions LLC now owns 2,201 shares of the insurance provider's stock valued at $840,000 after buying an additional 1,410 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Humana by 337.1% in the 3rd quarter. Meeder Asset Management Inc. now owns 2,885 shares of the insurance provider's stock valued at $1,101,000 after buying an additional 2,225 shares during the period. Composition Wealth LLC lifted its holdings in shares of Humana by 20.7% in the 3rd quarter. Composition Wealth LLC now owns 1,086 shares of the insurance provider's stock valued at $415,000 after buying an additional 186 shares during the period. Finally, Rothschild Investment LLC grew its holdings in Humana by 9.4% during the third quarter. Rothschild Investment LLC now owns 279 shares of the insurance provider's stock worth $106,000 after acquiring an additional 24 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.
About Humana
(
Get Free Report)
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.